Press Releases

Initiative Features Compelling Stories Celebrating That People are "Made of More" Than Their Head and Neck Cancer Diagnosis, Along With Resources to Help People Impacted Find Support and Community...

Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup...

Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer Research from the...

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN®, "eribulin") will be presented during the 2022 San Antonio...

Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022 /PRNewswire/ -- Eisai today announced final...